vs
Side-by-side financial comparison of Cytosorbents Corp (CTSO) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $9.2M, roughly 1.4× Cytosorbents Corp). SOLESENCE, INC. runs the higher net margin — 1.3% vs -59.5%, a 60.8% gap on every dollar of revenue. On growth, Cytosorbents Corp posted the faster year-over-year revenue change (0.9% vs -0.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs 1.3%).
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CTSO vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $12.5M |
| Net Profit | $-5.5M | $163.0K |
| Gross Margin | 73.7% | 27.5% |
| Operating Margin | -47.5% | 1.5% |
| Net Margin | -59.5% | 1.3% |
| Revenue YoY | 0.9% | -0.7% |
| Net Profit YoY | 27.4% | 129.2% |
| EPS (diluted) | $-0.09 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $12.5M | ||
| Q3 25 | $9.5M | $14.6M | ||
| Q2 25 | $9.6M | $20.4M | ||
| Q1 25 | $8.7M | $14.6M | ||
| Q4 24 | $9.2M | $12.6M | ||
| Q3 24 | $8.6M | $16.9M | ||
| Q2 24 | $8.8M | $13.0M | ||
| Q1 24 | $9.0M | $9.9M |
| Q4 25 | $-5.5M | $163.0K | ||
| Q3 25 | $-3.2M | $-1.1M | ||
| Q2 25 | $1.9M | $2.7M | ||
| Q1 25 | $-1.5M | $80.0K | ||
| Q4 24 | $-7.6M | $-559.0K | ||
| Q3 24 | $-2.8M | $3.0M | ||
| Q2 24 | $-4.3M | $856.0K | ||
| Q1 24 | $-6.1M | $893.0K |
| Q4 25 | 73.7% | 27.5% | ||
| Q3 25 | 70.3% | 23.1% | ||
| Q2 25 | 70.9% | 28.9% | ||
| Q1 25 | 71.1% | 23.1% | ||
| Q4 24 | 68.4% | 22.0% | ||
| Q3 24 | 61.0% | 36.2% | ||
| Q2 24 | 73.5% | 28.7% | ||
| Q1 24 | 76.5% | 36.3% |
| Q4 25 | -47.5% | 1.5% | ||
| Q3 25 | -30.2% | -5.4% | ||
| Q2 25 | -37.6% | 9.4% | ||
| Q1 25 | -44.5% | 1.8% | ||
| Q4 24 | -37.1% | -1.8% | ||
| Q3 24 | -56.1% | 19.0% | ||
| Q2 24 | -40.4% | 8.0% | ||
| Q1 24 | -51.8% | 11.3% |
| Q4 25 | -59.5% | 1.3% | ||
| Q3 25 | -33.4% | -7.7% | ||
| Q2 25 | 20.2% | 13.1% | ||
| Q1 25 | -16.9% | 0.5% | ||
| Q4 24 | -82.7% | -4.4% | ||
| Q3 24 | -32.1% | 18.1% | ||
| Q2 24 | -48.6% | 6.6% | ||
| Q1 24 | -67.7% | 9.0% |
| Q4 25 | $-0.09 | $0.00 | ||
| Q3 25 | $-0.05 | $-0.02 | ||
| Q2 25 | $0.03 | $0.04 | ||
| Q1 25 | $-0.02 | $0.00 | ||
| Q4 24 | $-0.14 | $0.00 | ||
| Q3 24 | $-0.05 | $0.04 | ||
| Q2 24 | $-0.08 | $0.01 | ||
| Q1 24 | $-0.11 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.2M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9M | $17.6M |
| Total Assets | $44.2M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.2M | $1.3M | ||
| Q3 25 | $7.5M | $429.0K | ||
| Q2 25 | $10.2M | $4.1M | ||
| Q1 25 | $11.6M | $1.8M | ||
| Q4 24 | $3.3M | $1.4M | ||
| Q3 24 | $5.7M | $2.9M | ||
| Q2 24 | $8.5M | $2.4M | ||
| Q1 24 | $8.6M | $2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $4.4M | — |
| Q4 25 | $5.9M | $17.6M | ||
| Q3 25 | $9.0M | $17.2M | ||
| Q2 25 | $11.6M | $18.2M | ||
| Q1 25 | $14.5M | $15.2M | ||
| Q4 24 | $11.1M | $14.9M | ||
| Q3 24 | $13.4M | $15.2M | ||
| Q2 24 | $17.4M | $11.9M | ||
| Q1 24 | $19.6M | $5.0M |
| Q4 25 | $44.2M | $50.1M | ||
| Q3 25 | $45.8M | $54.0M | ||
| Q2 25 | $48.0M | $60.0M | ||
| Q1 25 | $50.8M | $57.0M | ||
| Q4 24 | $47.4M | $50.0M | ||
| Q3 24 | $47.8M | $48.0M | ||
| Q2 24 | $53.4M | $40.8M | ||
| Q1 24 | $47.1M | $38.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.23× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $1.8M |
| Free Cash FlowOCF − Capex | $-4.9M | — |
| FCF MarginFCF / Revenue | -53.4% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.8M | $1.8M | ||
| Q3 25 | $-2.6M | $-2.5M | ||
| Q2 25 | $-1.5M | $-654.0K | ||
| Q1 25 | $-3.5M | $-7.2M | ||
| Q4 24 | $-2.3M | $2.2M | ||
| Q3 24 | $-2.5M | $4.2M | ||
| Q2 24 | $-4.8M | $-565.0K | ||
| Q1 24 | $-4.8M | $-3.9M |
| Q4 25 | $-4.9M | — | ||
| Q3 25 | $-2.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-3.5M | — | ||
| Q4 24 | $-2.4M | $-404.0K | ||
| Q3 24 | $-2.6M | $2.8M | ||
| Q2 24 | $-4.8M | $-1.0M | ||
| Q1 24 | $-4.9M | $-3.9M |
| Q4 25 | -53.4% | — | ||
| Q3 25 | -27.3% | — | ||
| Q2 25 | -16.1% | — | ||
| Q1 25 | -39.7% | — | ||
| Q4 24 | -26.3% | -3.2% | ||
| Q3 24 | -30.4% | 16.6% | ||
| Q2 24 | -54.4% | -8.0% | ||
| Q1 24 | -54.2% | -39.9% |
| Q4 25 | 1.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.8% | 20.6% | ||
| Q3 24 | 1.8% | 8.3% | ||
| Q2 24 | 0.2% | 3.7% | ||
| Q1 24 | 0.5% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.78× | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
SLSN
Segment breakdown not available.
